logo

SPSA News

Email Updates

Prostate Cancer News: Below you will find news articles in chronological order (latest at the top). You will find interesting news, events, stories, latest testing and research, activities and much more.

Dec
9th
2020

Subject: NICE questionnaire on radiotherapy spacer

Category: New Treatments

If you have had a spacer used to protect your rectum during radiotherapy, your experiences could help NICE decide if the procedure should be used more widely in the NHS.

The National Institute for Health and Care Excellence (NICE) is carrying out a project on the procedure ‘Biodegradable spacer insertion to protect the rectum during radiotherapy for prostate cancer.’ They are looking at how well the procedure is working and if it is safe enough to be used more widely in the NHS in the future.

Radiotherapy to treat prostate cancer can damage the rectum (the end part of the bowel) causing bleeding and leakage of faeces (poo). The aim of this procedure is to reduce the amount of radiation reaching the rectum during radiotherapy, which may reduce the damage. It is usually done using general anaesthetic about 1 week before radiotherapy starts. The rectum is pushed slightly away from the prostate by inserting gel or a balloon (spacer) between them. This remains in place during radiotherapy. It is biodegradable, which means it breaks down and is absorbed by the body after about 6 months.

If this is a procedure that you have had, NICE would like to invite you to provide feedback on your experience of it by completing a survey, which should take no more than 10 minutes to complete. If this is a procedure that you have not had, please do not complete this survey.

If you would like to find out more about NICE or the programme please visit their website.

https://nice.researchfeedback.net/s/IP1316_2

Source: NICE / Prostate Cancer Research

Oct
26th
2020

Subject: Somerset Prostate Support Association AGM

Category: Somerset News

SPSA Annual General Meeting


Due to the continuing Covid-19 situation, there will NOT be an AGM this year. The situation will be reviewed in January 2021 

Source: SPSA

Sep
3rd
2020

Subject: Prostate Cancer and Transgender Women

Category: Prostate Cancer News

Prostate cancer is reported as the most common cancer in UK males. However, there is very little research on prostate cancer in trans women. The available research suggests several things:

Trans women have a prostate gland, but it is often neglected

  • It is easy to forget about something that has never caused you any trouble! Doctors can be nervous or anxious about talking to trans women about their prostate, and sometimes trans women don’t know about their prostate. If you experience any new symptoms (see below) that you think might relate to your prostate, see your healthcare professional for advice.

Trans women who have had lifelong lower T levels appear to have a lower risk of prostate cancer.

  • Research in trans women with prostate cancer does show that most cases have been diagnosed in those who began gender-affirming hormones in later life. Therefore, if you started hormones earlier in life, and thus had lower T levels for longer, you appear to be at lower risk of prostate cancer. 
  • Like most trans healthcare research, the evidence is scant, and you should always see your healthcare provider if you are concerned about any aspect of your health. 
  • Evidence from a 2016 study showed no relationship between testosterone levels and prostate cancer risk.
  • Gender-affirming hormones do not eliminate your risk of prostate cancer.

Trans women who start HRT later in life should consider prostate screening in the same way that cis men should

  • If you still have a prostate, you should always be aware of the risk of cancer and see your healthcare provider if you have any symptoms of prostate cancer or concerns about your health generally.
  • Your risk of prostate cancer increases with age, regardless of your hormone profile.

Source: GenderGP